Abstract:To explore novel topoisomerase inhibitors with high activity and druggability, 3-aryl isoquinoline alkaloids based on the corydamine modification and preliminary SARs of isoquinoline alkaloids in our previous works were re-designed. Currently, the design strategy is mainly revolved around the rigidity and flexibility of the molecular side chain and the molecular size. Consequently, not only the activity and druggability of the compound could be further improved, also the mechanism behind could been discovered. In vitro pharmacological studies, the outstanding nature with the excellent activity and the researchable depth of azepane-substituted compound 7 has been found through the vitro cytotoxicity test (IC50 = 1.93 μM in HuH7 cells and 2.10 μM in LM9 cells) and topoisomerase test. It was found that compound 7 had dual inhibitory effects on topoisomerase I and II, and its inhibitory activity on topoisomerase II is stronger than the positive drug etoposide. From the perspective of molecular docking, it had been verified that compound 7 could insert between DNA base pairs, which was consistent with the results of the DNA unwinding experiment. And the comet experiment confirmed 7 caused DNA damage. Meanwhile, compound 7 could inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Therefore, this study may lay a foundation for the discovery of 3-arylisoquinoline compounds with anti-liver cancer potential.

A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell.

A Novel Dna Topoisomerase I Inhibitor with Different Mechanism from Camptothecin Induces G2/M Phase Cell Cycle Arrest to K562 Cells

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

Synthesis, Cytotoxicity and Structure-Activity Relationship of Indolizinoquinolinedione Derivatives As DNA Topoisomerase IB Catalytic Inhibitors

Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives As Potential Topoisomerase I Inhibitors by Scaffold Modification.

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Synthesis and Biological Research of Novel Azaacridine Derivatives As Potent DNA-binding Ligands and Topoisomerase II Inhibitors

CS1 is a Novel Topoisomerase IIα Inhibitor with Favorable Drug Resistance Profiles.

Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives As Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Discovery Of Dna Topoisomerase I Inhibitors With Low-Cytotoxicity Based On Virtual Screening From Natural Products

Design, Synthesis, and Cytotoxicity of Indolizinoquinoxaline-5,12-Dione Derivatives, Novel Dna Topoisomerase Ib Inhibitors

Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.

Design and synthesis of Aza-boeravinone derivatives as potential novel topoisomerase I inhibitors

Synthesis of novel pyrazole derivatives as promising DNA-binding agents and evaluation of antitumor and antitopoisomerase I/II activities.

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

Synthesis and Biological Evaluation of Xanthone Derivatives As Anti-Cancer Agents Targeting Topoisomerase II and DNA

Natural inhibitors of DNA topoisomerase I with cytotoxicities.

Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets

Design, Synthesis and Biological Evaluation of 3-Arylisoquinoline Derivatives As Topoisomerase I and II Dual Inhibitors for the Therapy of Liver Cancer.

Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives As Nonintercalative Topoisomerase II Catalytic Inhibitors.

A Unique Topoisomerase II Inhibitor with Dose-Affected Anticancer Mechanisms and Less Cardiotoxicity